Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 19/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19190767 | 0.91 | MME (0.55) | MME | |
| SCHEMBL9930130 | 0.89 | MME (0.68) | MME | |
| Trifluoroacetic Acid SCHEMBL29582463 | 0.85 | MME (0.63) | MME | |
| SCHEMBL9930086 | 0.84 | MME (0.56) | MME | |
| SCHEMBL9941241 | 0.82 | MME (0.51) | MME | |
| SCHEMBL9930079 | 0.82 | MME (0.51) | MME | |
| SCHEMBL9930092 | 0.82 | MME (0.51) | MME | |
| SCHEMBL9940911 | 0.82 | MME (0.51) | MME | |
| SCHEMBL9940924 | 0.82 | MME (0.59) | MME | |
| SCHEMBL9929620 | 0.82 | MME (0.59) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11261197-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-10829438-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759813-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-01 | — | — | US | disclosed |
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8586536-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586536-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759813-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885 |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | BTK, LYN, SYK | MME 3241/4885 |
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885 |
| US-10829438-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885 |
| US-11261197-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885 |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885 |
| US-20140046053-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885 |
| US-20120157383-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.